Driving innovation in surgical precision with its AI-powered Surgical Precision Enhancement system, which enhances outcomes in robot-assisted and laparoscopic surgeries. A goal that is personally significant to the founder and CEO, a cancer survivor who endured multiple surgeries and complications. Designed to reduce complications and reoperations, SPE leverages real-time 3D mapping and advanced tissue recognition, offering surgeons unparalleled accuracy without disrupting existing workflows.
Positioned in a $10.1B global market, the company is on the verge of clinical testing in major hospitals and seeks $3M to complete development and secure FDA approval, targeting revenue generation within 24 months. Its patented technology and strategic partnerships set it apart from competitors, making it a strong candidate for investment.
Let us know, if you'd like to request more information about the company, or if you'd like to hear a great pitch first.
Contact Us